Coeptis Therapeutics
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (NCT04901416) | Coeptis Therapeutics | 2021-12-15 |
| Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19 (NCT04900454) | Coeptis Therapeutics | 2021-08-01 |
Track Coeptis Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.